Company Profile

Icogenex Corporation (AKA: Icogen Corporation)
Profile last edited on: 2/11/20      CAGE: 47D75      UEI:

Business Identifier: Identification of protein effectors for development of therapeutic drugs
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

454 North 34th Street
Seattle, WA 98112
   (206) 545-2880
Location: Single
Congr. District: 07
County: King

Public Profile

Previously called Icogen Corporation, Icogenex is using ICOCEPTTM, its platform technology, to identify therapeutically useful molecules for the treatment of inflammatory diseases, Alzheimer's disease, and diseases involving inappropriate proteolytic processing.proven capabilities in expressing proteins from bacteria, yeast and mammalian cells. With proven capabilities in expressing proteins from bacteria, yeast and mammalian cell., the company partners with pharmaceutical companies, provides contract research services and leverages in-house drug development projects to express therapeutic proteins.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2009 1 NIH $371,270
Project Title: Substrate Based Proteolytic Inhibitors For The Treatment Of Huntington's Disease
2005 1 NIH $369,148
Project Title: Alzheimer's Therapeutic Derived from a Natural Product
2004 2 NIH $1,088,827
Project Title: Novel agonists and antagonists of chemokine receptors
2003 1 NIH $369,888
Project Title: Effector of APP to Lower Amount of beta-Amyloid Protein
2001 2 NIH $451,403
Project Title: Affinity And Transcriptase Technologies

Key People / Management

  Frederick S Hagen -- President

  Joseph Day

  Theo Devos

  Jerry McGuire -- CFO

  Richard A Swank

  David Webster -- Director Business Development

Company News

There are no news available.